---
title: "Factors Associated with the Deterioration of Post-COVID-19 Condition Symptoms Following a Dose of SARS-CoV-2 Vaccine"
tags:
- ‚ûï 2026-01-25
- üíä Treatment
created: '2026-01-09'
published: '2026-01-09'
---

<details>
<summary>Beidari et al. (2026)</summary>

- **Authors:** Malika Seydou Beidari, Martyne Audet, St√©phane Turcotte, Raoul Daoust, Patrick Archambault, Simon Decary, Richard Fleet, Alexis Cournoyer, Judith Fafard, Eric Mercier
- **Institutes:** Centre de recherche du CHU de Qu√©bec-Universit√© Laval, Qu√©bec, QC, Canada, Centre de recherche int√©gr√©e pour un syst√®me de sant√© apprenant en sant√© et services sociaux, L√©vis, QC, Canada, D√©partement de m√©decine de famille et de m√©decine d'urgence, Universit√© de Montr√©al, Montr√©al, QC, Canada
- **Publisher:** medRxiv
- **Link:** [DOI](https://doi.org/10.1101/2026.01.06.26343459)

</details>

## Summary

This study identifies specific risk factors that may predict a worsening of Long COVID symptoms following vaccination. While most patients do not experience a decline, identifying those at higher risk‚Äîsuch as those receiving the Moderna vaccine or having a history of persistent cough‚Äîallows for more personalized medical guidance. These findings contribute to the ongoing discussion regarding the immunological interaction between vaccines and existing Post-COVID-19 Condition (PCC).

## What was researched?

The study investigated which factors are associated with the deterioration of Post-COVID-19 Condition (PCC) symptoms in patients who received a SARS-CoV-2 vaccine dose at least 90 days after their initial infection.

## Why was it researched?

While vaccination generally helps prevent severe disease, some patients with Long COVID report a worsening of their symptoms after immunization. Researchers sought to identify clinical or demographic characteristics that could explain this phenomenon.

## How was it researched?

This multicenter cohort study analyzed 476 patients from 33 Canadian emergency departments who met the WHO definition for PCC. Data were collected through telephone questionnaires, and researchers used logistic regression models to identify significant associations between patient factors and symptom changes.

## What has been found?

The study found that 28.8% of participants reported a deterioration in their symptoms after vaccination. Two factors were significantly linked to this decline: receiving the Moderna (mRNA-1273) üíä vaccine and having a persistent cough three months after the initial infection. No significant associations were found for age or sex.

## Discussion

The results suggest that the type of vaccine and specific initial symptoms might influence the post-vaccination course for PCC patients. Limitations include the reliance on self-reported data and the lack of a control group not receiving a vaccine.

## Conclusion & Future Work

Post-infection vaccination may increase the risk of symptom deterioration in specific PCC subgroups. Future research should focus on the underlying immunological mechanisms and tailoring vaccination strategies for patients already suffering from Long COVID.

